Chemotherapy Induced Thrombocytopenia Therapeutics:Risk Factors and PathophysiologyChemotherapy induced thrombocytopenia (CIT) is a common side effect of many cancer treatment regimens that can greatly impact a patient's quality of life. Certain chemotherapeutic agents are more likely to cause thrombocytopenia than others due to their mechanism of action. Specifically, drugs that are associated with myelosuppression such as alkylating agents, anthracyclines, and antimetabolites have a higher risk of inducing thrombocytopenia. Patient-specific factors like older age, preexisting cytopenias, liver or kidney dysfunction, and poor performance status can also increase susceptibility.

The cause of Chemotherapy Induced Thrombocytopenia Therapeutics is hematopoietic toxicity resulting in impaired production and accelerated clearance of platelets from the bloodstream. Chemotherapy damages hematopoietic stem and progenitor cells in the bone marrow, interrupting normal thrombopoiesis. At the same time, injured marrow endothelial cells and im